Compare ADMA Biologics Inc (ADMA) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Phillips 66 — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Phillips 66 trades at $224.36 (market cap $86.00B). The key difference: Phillips 66 is far larger — about 39.4× ADMA Biologics Inc's market cap, and Phillips 66 pays a 2.36% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PSX | |
|---|---|---|
Market Cap | $2.18B | $86.00B |
Sector | Health | Energy |
52-Week High | $20.38 | $224.36 |
52-Week Low | $7.60 | $120.04 |
Enterprise Value | $2.25B | $102.46B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Phillips 66 (PSX) trades at $203.91, down 0.78% on the day, with a bearish technical signal but strong fundamental tailwinds from refining margins. Recent Q2 2026 earnings of $9.41 per share beat estimates, driven by high utilization and robust cash flow. The stock has support near $201 and resistance at $206, with a consensus price target of $221.92 suggesting upside potential.
Outlook is positive due to sustained refining profitability and debt reduction, but risks include volatile crude prices and geopolitical tensions. Analysts are predominantly bullish (57% buy ratings), though technical indicators warn of near-term pressure. Investors should weigh strong fundamentals against sector cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
